Abstract: The present disclosure discloses an in-vitro and non-invasive method for detecting a medical condition in a subject. The method involves enriching very small embryonic like stem cells from the sample, to obtain a mixture comprising said very small embryonic like stem cells; obtaining nucleic acid from the mixture of step; performing an assay with the nucleic acid for analysing expression level of Oct4A in the very small embryonic like stem cells from the sample; and comparing the expression level of Oct4A in the very small embryonic like stem cells from the sample with an expression level of Oct4A in a control sample. The present disclosure also provides a method for predicting the onset of cancer and for predicting the presence of cancer. A method of treating cancer is also disclosed herein. Moreover, a reagent kit and a detection kit are also disclosed.

Abstract: The present disclosure discloses a method for detecting a medical condition, in particular cancer, in a subject using blood sample by analyzing very small embryonic like stem cells. The present disclosure also provides with methods of detecting a medical condition or cancer in a subject by analyzing the expression of Oct4A marker in blood sample. The method as disclosed herein is simple, quick, non-invasive and specific.

Abstract: The present disclosure discloses an in-vitro method for detecting presence of metabolically altered cells. Also, an in-vitro method for detecting presence of quiescent cells has been disclosed. The present disclosure discloses an in-vitro method for detecting and predicting presence of cancer. The present disclosure discloses an in-vitro method for monitoring response to anti-cancer therapy. The present disclosure analyses expression of at least one biomarker of pluripotent stem cell for detecting or predicting or monitoring cancer. A related use of the at least one biomarker of pluripotent stem cell marker along with a method of treatment comprising the in-vitro method of detection or prediction has been disclosed herewith.

Abstract: The present disclosure discloses an in-vitro method for detecting presence of metabolically altered cells. Also, an in-vitro method for detecting presence of quiescent cells has been disclosed. The present disclosure discloses an in-vitro method for detecting and predicting presence of cancer. The present disclosure discloses an in-vitro method for monitoring response to anti-cancer therapy. The present disclosure analyses expression of at least one biomarker of pluripotent stem cell for detecting or predicting or monitoring cancer. A related use of the at least one biomarker of pluripotent stem cell marker along with a method of treatment comprising the in-vitro method of detection or prediction has been disclosed herewith.

Abstract: The present disclosure discloses an in-vitro and non-invasive method for detecting a medical condition in a subject. The method involves enriching very small embryonic like stem cells from the sample, to obtain a mixture comprising said very small embryonic like stem cells; obtaining nucleic acid from the mixture of step; performing an assay with the nucleic acid for analysing expression level of Oct4A in the very small embryonic like stem cells from the sample; and comparing the expression level of Oct4A in the very small embryonic like stem cells from the sample with an expression level of Oct4A in a control sample. The present disclosure also provides a method for predicting the onset of cancer and for predicting the presence of cancer. A method of treating cancer is also disclosed herein. Moreover, a reagent kit and a detection kit are also disclosed.

Abstract: The present disclosure discloses an in-vitro and non-invasive method for detecting a medical condition in a subject. The method involves enriching very small embryonic like stem cells from the sample, to obtain a mixture comprising said very small embryonic like stem cells; obtaining nucleic acid from the mixture of step; performing an assay with the nucleic acid for analysing expression level of Oct4A in the very small embryonic like stem cells from the sample; and comparing the expression level of Oct4A in the very small embryonic like stem cells from the sample with an expression level of Oct4A in a control sample. The present disclosure also provides a method for predicting the onset of cancer and for predicting the presence of cancer. A method of treating cancer is also disclosed herein. Moreover, a reagent kit and a detection kit are also disclosed.

Abstract: The present disclosure discloses an in-vitro method for detecting presence of metabolically altered cells. Also, an in-vitro method for detecting presence of quiescent cells has been disclosed. The present disclosure discloses an in-vitro method for detecting and predicting presence of cancer. The present disclosure discloses an in-vitro method for monitoring response to anti-cancer therapy. The present disclosure analyses expression of at least one biomarker of pluripotent stem cell for detecting or predicting or monitoring cancer. A related use of the at least one biomarker of pluripotent stem cell marker along with a method of treatment comprising the in-vitro method of detection or prediction has been disclosed herewith.

Abstract: The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.

Abstract: A method for retrieving phase information in a coherent diffraction imaging process includes acquiring a plurality of 3D data sets, each 3D data set corresponding to one of a plurality of time states, and reconstructing a 3D image of the object at a given time state using the 3D data set from all of the time states. Each 3D data set is acquired by: illuminating an object positioned in a first position with a coherent beam; measuring a first 2D diffraction pattern using an area detector; rotating the object around a tilt axis thereof to a second position that is different from the first position; re-illuminating the object positioned in the second position with the coherent beam; re-measuring a second 2D diffraction pattern using the area detector; and repeating the rotating, re-illuminating and re-measuring steps such that each 3D data set includes a predetermined number of diffraction patterns.

Abstract: A method for retrieving phase information in a coherent diffraction imaging process includes acquiring a plurality of 3D data sets, each 3D data set corresponding to one of a plurality of time states, and reconstructing a 3D image of the object at a given time state using the 3D data set from all of the time states. Each 3D data set is acquired by: illuminating an object positioned in a first position with a coherent beam; measuring a first 2D diffraction pattern using an area detector; rotating the object around a tilt axis thereof to a second position that is different from the first position; re-illuminating the object positioned in the second position with the coherent beam; re-measuring a second 2D diffraction pattern using the area detector; and repeating the rotating, re-illuminating and re-measuring steps such that each 3D data set includes a predetermined number of diffraction patterns.

Abstract: The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.

Abstract: A hand-held chemical vapor detector for detecting biological substances in an indoor and outdoor setting is claimed. More specifically, the present invention relates to a plasma chromatograph (PC) vapor detector that is interfaced to a biological sample processing and transfer introduction system. The biological sample processing was accomplished by quartz tube thermal decomposition (TD), and the resultant vapor was transferred by gas chromatography (GC) to the PC detector. This system is comprised of a thermal decomposition module, gas chromatography module and a plasma chromatograph detector. These components are connected in a series fashion. The device is referred to as a Biological Classifier System (BCS). The BCS can be described as a hyphenated device where two analytical dimensions (the GC and PC), in series, allow the separation and isolation of individual components from the thermal decomposition of biological analytes.